Eric Victory is Vice President & Head for cardiovascular, metabolic, and infectious diseases within the MedImmune Partnering & Strategy group. In this role he is responsible for leading the company’s early (pre-proof of concept) biologic externalization activities in two of our therapeutic areas, and for working with the CV/Metabolic and ID/Vaccines iMed Leadership Teams to drive and define the respective therapeutic area strategies within MedImmune. In this role, Eric has successfully closed the acquisitions of Spirogen and Amplimmune, brought on Sanofi Pasteur as a partner in developing MedImmune’s MEDI8897 RSV antibody, and led key agreements with Inovio Pharmaceuticals, Omnis Pharmaceuticals, the Joslin Diabetes Center, Shionogi, Advaxis, Immunocore, ADC Therapeutics, and NGM Biopharmaceuticals, all signed since the summer of 2013.
Prior to taking the Partnering and Strategy role in 2013, Eric was part of the MedImmune Corporate Development and Ventures team since 2010, with responsibility for business development and licensing transactions with university, academic, and non-profit institutions and in the cardiovascular, gastrointestinal, and metabolic disease therapeutic area, as well as oversight of MedImmune’s pandemic influenza contracts with the United States Government. Eric joined MedImmune in 2002 as a Product Manager in MedImmune’s Marketing Department and worked on Synagis (palivizumab), CytoGam (CMV-IVIG) and RespiGam (RSV-IVIG). In 2006 Eric joined MedImmune’s Business Development Department where he has worked on licensing transactions across a range of therapeutic areas, including completing licenses with Trellis Biosciences, Immune Design Corporation, and Amgen, as well as out-licenses of MedImmune’s reverse genetics intellectual property estates. Eric holds undergraduate degrees in physics and political sciences from Stanford University, and an MBA from Northwestern University’s Kellogg School of Management.
Prior to his time at MedImmune, Eric was a commissioned officer in the United States Navy Nuclear Propulsion Program.